Table 2.

Patient characteristics, treatment and outcome

No	Age/sex	Primary/Secondary	ECOG	LDH	BSx	Presentation	Site	Treatment	CTX Type	CNS Response	Status	OS (y)
1	38/F	Primary	0	Normal	No	Altered sensation bilateral upper limbs	C6 intramedullary cord	SX, CTx, RTx	MTX	CRu	Alive	1.4
2	78/F	Primary	1	Normal	No	Left hemiparesis	Right frontotemporal and parietal dura invading skull and temporalis muscle	SX, CTx	R‐CHOP + MTX	CRu	Alive	0.54
3	51/F	Primary	0	Unknown	No	Personality change	Left frontal dura	SX, CTx	R‐CHOP + MTX	CR	Alive	2.05
4	51/M	Primary	2	Normal	No	Unknown	Unknown	Unknown	N/A	CRu	Alive	2.41
5	26/M	Primary	0	Normal	No	Altered sensation face	Left medial temporal lobe dura	SX, CTx	R‐CHOP	CR	Alive	9.49
6	62/M	Primary	0	Normal	No	Seizure	Left fronto‐parietal region dura	SX, CTx, RTx	R	CR	Alive	3.84
7	54/F	Primary	0	Normal	No	Visual changes	Dura overlying tuberculum sella, suprasellar cistern, sella turcica	SX, RTx	N/A	CR	Alive	5.15
8	34/M	Primary	0	Normal	No	Seizure	Right temporal lobe	SX, RTx	N/A	CR	Alive	8.22
9	78/F	Primary	1	Elevated	No	Headaches	Dura of overlying cavernous sinus	SX, CTx	BR + MTX (IT) / Ara‐C (IT)	Unknown	Alive	0.34
10	30/F	Primary	0	Elevated	No	Diplopia and ptosis	Dura overlying cavernous sinus	SX, RTx	N/A	PR	Alive	1.89
11	66/F	Primary	1	Elevated	No	Left facial palsy and left hemiparesis	Right basal ganglia	SX, CTx, RTx	R + MTX	Progressive	Alive	1.76
12	50/F	Primary	0	Normal	No	Altered sensation	Dura overlying left temporal region	SX, RTx	N/A	CRu	Alive	0.41
13	61/F	Primary	0	Normal	No	Seizure, speech disturbance	Dura of left cerebral convexity	SX, RTx	N/A	CRu	Alive	1.15
14	77/M	Secondary	0	Normal	Present	Visual loss	Left optic nerve	CTx	R‐CHOP + MTX (IT)	Died	Dead	0.1
15	59/M	Secondary	0	Normal	No	Scalp swelling, dysarthria	Right frontoparietal dura	CTx	CVPR	CR	Alive	11.44
16	66/F	Secondary	3	Elevated	Present	Headaches, fevers, fatigue	Frontal lobe, occipital lobe, cerebellum	CTx	MTX (IT) + Ara‐C (IT)	PR	Dead	0.583
17	53/F	Secondary	3	Unknown	Unknown	Unknown	Left frontal lobe	RTx	N/A	PR	Dead	1.74
18	66/M	Secondary	0	Elevated	No	Visual changes	Right posterior parieto‐occipital lobe	SX, RTx	N/A	Died	Dead	0.16
19	67/F	Secondary	0	Normal	No	Unknown	Unknown	Unknown	N/A	Unknown	Alive	3.01
20	67/M	Secondary	1	Normal	No	Unknown	Unknown	Unknown	N/A	PR	Alive	1.34
21	46/F	Secondary	0	Normal	No	Unknown	Unknown	CTx	FDR + Ara‐C	CRu	Alive	3.45
22	57/F	Secondary	0	Unknown	No	Personality change, unsteadiness, memory loss	Surrounding lateral and third ventricles	CTx	IFO + Ara‐C + MTX	Unknown	Alive	Unknown
23	34/M	Secondary	0	Elevated	No	Altered sensation	Dural based sacral spinal canal	SX, CTx, RTx	R‐CHOP	CR	Alive	4.22
24	62/M	Secondary	1	Normal	No	Headaches, pain in V2 distribution of trigeminal nerve	Dura overlying optic nerves, pterygopalatine fossa, cavernous sinus, optic chiasm	SX, CTx	R	Progressive	Alive	1.57
25	69/F	Secondary	1	Elevated	No	Visual changes	Dura of right orbit and skull base	SX, RTx	N/A	Progressive	Alive	1.6
26	60/F	Secondary	1	Normal	No	Altered sensation	Skull base leptomeinges and extradural space C2‐C4	SX, CTx	Ibrutinib + R	Unknown	Alive	0.09

Abbreviations: Ara‐C, cytarabine; BR, bendamustine rituximab; BSx, B symptoms; CR complete response; Cru, complete response unconfirmed; CTx, chemotherapy; CVPR, cyclophosphamide, vincristine, prednisolone, rituximab; F, female; FDR, fludarabine; IFO, ifosfamide; IT, intrathecal; M, male; MTX, methotrexate; N/A, not applicable; OS, overall survival; PR, partial response; Progressive, progressive disease; R, rituximab; R‐CHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone; RTx, radiotherapy; SX, surgery.